May 01, 2014

Boehringer Ingelheim Vetmedica, Inc., Launches ULTRA™ Fel-O-Vax®,the First and Only ½ mL Vaccine Line for Cats

Company continues revolutionary approach to veterinary care with low-dose vaccines to improve overall vaccine experience for cats

Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the launch of ULTRA™ Fel-O-Vax®, the first ½ mL vaccine line for cats. ULTRA™ Fel-O-Vax® joins its partner canine product line, ULTRA™ Duramune®, as the only pet vaccine lines on the market with 50 percent less volume per dose.

“The goal of our ULTRA™ Fel-O-Vax® and ULTRA™ Duramune® vaccines is to offer veterinarians options when it comes to their vaccine protocols," says Kyle Malter, DVM, technical manager, pet vaccines, BIVI. “ULTRA™ Fel-O-Vax® provides a more comfortable vaccine experience for the animal, while continuing to afford veterinarians the same uncompromised, efficacious protection as BIVI’s 1 mL vaccines.”

Built on the foundation of the Fel-O-Vax® vaccine line, ULTRA™ Fel-O-Vax® features the same proven level of efficacy the industry has come to expect from BIVI pet vaccines for over 30 years.

ULTRA™ Fel-O-Vax® is manufactured with PureFil™ Technology, which includes improved purification processes and tighter manufacturing profiles, resulting in more serial-to-serial consistency. PureFil™ Technology is designed to reduce vaccine reactions associated with extraneous proteins and cellular debris.

ULTRA™ Fel-O-Vax® was created with both patients and pet owners in mind. As a 0.5 mL feline vaccine line, ULTRA™ Fel-O-Vax® allows less vaccine volume to be injected over the lifetime of the cat. 85 percent of cat owners believe that reducing injection volume over the lifetime of their cats is important, according to a recent survey of pet owners.1

The recent research also found that the vast majority (92 percent) of cat owners highly value a vaccine that incorporates the latest in purification technology and reduced injection volume.1

"ULTRA™ Fel-O-Vax® offers veterinarians the opportunity to provide best medicine to their feline patients with less vaccine volume and the same efficacy.

We believe this groundbreaking vaccine offers a more comfortable patient experience and leads to better owner compliance for next year’s visit,” says Malter.

The ULTRA™ Fel-O-Vax® vaccine line is available in core and non-core combinations to more closely align with AAFP Feline Vaccination guidelines, including BIVI’s exclusive dual-strain calicivirus (FCV) for better crossneutralization and near-perfect, proven feline leukemia (FeLV) protection.

For more information on the ULTRA™ Fel-O-Vax® vaccine line, please visit:

1. BIVI Pet Owner Survey, 2014. Data on file.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit

Contact Information

  • Boehringer Ingelheim Vetmedica, Inc.

    Pet Division

    3902 Gene Field Road
    St. Joseph, Missouri 64506

    • Phone 866-638-2226
    • Fax 816-326-9167

Media Contact

Rene Ward

Director, U.S. Animal Health Communications
3902 Gene Field Road
St. Joseph, Missouri 64506